IL146232A0 - Use of dopamine d3 receptor ligands for producing medicaments for treating kidney disorders - Google Patents

Use of dopamine d3 receptor ligands for producing medicaments for treating kidney disorders

Info

Publication number
IL146232A0
IL146232A0 IL14623200A IL14623200A IL146232A0 IL 146232 A0 IL146232 A0 IL 146232A0 IL 14623200 A IL14623200 A IL 14623200A IL 14623200 A IL14623200 A IL 14623200A IL 146232 A0 IL146232 A0 IL 146232A0
Authority
IL
Israel
Prior art keywords
dopamine
receptor ligands
treating kidney
kidney disorders
producing medicaments
Prior art date
Application number
IL14623200A
Other languages
English (en)
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Publication of IL146232A0 publication Critical patent/IL146232A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL14623200A 1999-05-07 2000-04-28 Use of dopamine d3 receptor ligands for producing medicaments for treating kidney disorders IL146232A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19922443A DE19922443A1 (de) 1999-05-07 1999-05-07 Verwendung von Dopamin-D3-Rezeptorliganden zur Herstellung von Arzneimittel für die Behandlung von Nierenfunktionsstörungen
PCT/EP2000/003865 WO2000067847A2 (de) 1999-05-07 2000-04-28 Verwendung von dopamin-d3-rezeptorliganden zur herstellung von arzneimittel für die behandlung von nierenfunktionsstörungen

Publications (1)

Publication Number Publication Date
IL146232A0 true IL146232A0 (en) 2002-07-25

Family

ID=7908194

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14623200A IL146232A0 (en) 1999-05-07 2000-04-28 Use of dopamine d3 receptor ligands for producing medicaments for treating kidney disorders
IL146232A IL146232A (en) 1999-05-07 2001-10-30 Use of dopamine D3 receptor ligands to produce drugs to treat kidney disease

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL146232A IL146232A (en) 1999-05-07 2001-10-30 Use of dopamine D3 receptor ligands to produce drugs to treat kidney disease

Country Status (19)

Country Link
US (2) US7098214B1 (cs)
EP (1) EP1176963B1 (cs)
JP (3) JP4727822B2 (cs)
KR (2) KR100781828B1 (cs)
CN (2) CN1360502B (cs)
AT (1) ATE284693T1 (cs)
AU (1) AU770671B2 (cs)
BR (1) BR0010337A (cs)
CA (1) CA2368823C (cs)
CZ (1) CZ301832B6 (cs)
DE (2) DE19922443A1 (cs)
DK (1) DK1176963T3 (cs)
ES (1) ES2234597T3 (cs)
HU (1) HU228516B1 (cs)
IL (2) IL146232A0 (cs)
NO (1) NO329325B1 (cs)
PT (1) PT1176963E (cs)
WO (1) WO2000067847A2 (cs)
ZA (1) ZA200110044B (cs)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19922443A1 (de) * 1999-05-07 2000-11-09 Basf Ag Verwendung von Dopamin-D3-Rezeptorliganden zur Herstellung von Arzneimittel für die Behandlung von Nierenfunktionsstörungen
AU7989400A (en) 1999-10-01 2001-05-10 Smithkline Beecham Corporation Compounds and methods
US20020103198A1 (en) * 2000-12-04 2002-08-01 Fliri Anton F.J Acylamino cyclopropane derivatives
WO2002066446A1 (en) 2001-02-16 2002-08-29 Aventis Pharmaceuticals Inc. Heterocyclic substituted carbonyl derivatives and their use as dopamine d3 receptor ligands
EP1688412A3 (en) * 2001-02-16 2006-08-16 Aventis Pharmaceuticals, Inc. Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands
DE60216753T2 (de) * 2001-02-16 2008-01-03 Aventis Pharmaceuticals Inc. Heterocyclische harnstoffderivate und deren verwendung als dopamine d3 receptor liganden
DE10109867A1 (de) * 2001-03-01 2002-09-05 Abbott Gmbh & Co Kg Verwendung von Triazolverbindungen zur Prophylaxe und Therapie neurodegenerativer Erkrankungen, Hirntrauma und zerebraler Ischämie
DE10109866A1 (de) * 2001-03-01 2002-09-05 Abbott Gmbh & Co Kg Triazolverbindungen und deren Verwendung zur Prophylaxe und Therapie neurodegenerativer Erkrankungen, Hirntrauma und zerebraler Ischämie
WO2002078697A1 (en) * 2001-03-29 2002-10-10 Smithkline Beecham Corporation Compounds and methods
DE10131543A1 (de) * 2001-06-29 2003-01-16 Abbott Lab Pyrimidinoxyalkylpiperazine und ihre therapeutische Verwendung
HUP0103987A3 (en) * 2001-09-28 2004-11-29 Richter Gedeon Vegyeszet Phenylpiperazinylalkyl carboxylic acid amid derivatives, process for their preparation, pharmaceutical compositions containing them and their intermediates
AU2003214920A1 (en) 2002-02-04 2003-09-02 Millennium Pharmaceuticals Inc. Methods and compositions for treating hematological disorders
WO2004082569A2 (en) * 2003-03-17 2004-09-30 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with dopamine receptor d3 (drd3)
US20050137186A1 (en) 2003-12-18 2005-06-23 Abbott Gmbh & Co. Kg. Tetrahydrobenzazepines and their use
DE102004027358A1 (de) 2004-06-04 2005-12-29 Abbott Gmbh & Co. Kg Pyrimidinverbindungen und ihre Verwendung
WO2006015842A1 (en) * 2004-08-09 2006-02-16 Abbott Gmbh & Co. Kg 4-piperazinyl-pyrimidine compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor
MX2007004357A (es) 2004-10-14 2007-07-17 Abbott Gmbh & Co Kg Compuestos aminoetilaromaticos adecuados para tratar trastornos que responden a la modulacion del receptor de dopamina d3.
RU2442781C2 (ru) 2004-10-14 2012-02-20 Абботт ГмбХ унд Ко. КГ Арилсульфонилметильные или арилсульфонамидные производные ароматических соединений, фармацевтическая композиция на их основе и способ лечения расстройств, восприимчивых к лечению лигандами дофаминовых d3 рецепторов, с их помощью
CN101039904B (zh) 2004-10-14 2014-09-24 Abbvie德国有限责任两合公司 适于治疗对于多巴胺d3受体调节有反应的病症的杂环化合物
CN101039900B (zh) 2004-10-14 2012-03-21 艾博特股份有限两合公司 适合用于治疗应答多巴胺d3受体调节的疾病的6-氨基(氮杂)茚满化合物
WO2007120528A2 (en) * 2006-03-31 2007-10-25 La Jolla Pharmaceutical Company Inhibitors of semicarbazide-sensitive amine oxidase (ssao) and vap-1 mediated adhesion useful for treatment and prevention of diseases
KR20090035581A (ko) * 2006-08-04 2009-04-09 아지노모토 가부시키가이샤 신장 기능 장해 예방ㆍ치료제
EP2256109A4 (en) * 2008-01-25 2011-06-15 Univ Nihon APOPTOSIS INHIBITOR
KR20190028281A (ko) 2017-09-08 2019-03-18 주식회사 엑소코바이오 지방줄기세포 유래의 엑소좀을 유효성분으로 포함하는 조성물의 신장 기능 개선 용도

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE628766A (cs) * 1962-12-26
GB1087514A (en) * 1965-04-09 1967-10-18 Hitachi Ltd Arrangement for damping vibration of steam-turbine blades
DE4223921A1 (de) 1992-07-21 1994-01-27 Hartmut Prof Dr Med Oswald Herstellung und Verwendung von Hemmstoffen der DOPA-Decarboxylase sowie von Dopamin-Rezeptor-Antagonisten zur Bekämpfung der fortschreitenden Verschlechterung der Nierenfunktion beim Menschen
DE4425143A1 (de) * 1994-07-15 1996-01-18 Basf Ag Substituierte Pyrimidinverbindungen und deren Verwendung
DE19600934A1 (de) * 1996-01-12 1997-07-17 Basf Ag Substituierte Aza- und Diazacycloheptan- und Cyclooctanverbindungen und deren Verwendung
DE19922443A1 (de) * 1999-05-07 2000-11-09 Basf Ag Verwendung von Dopamin-D3-Rezeptorliganden zur Herstellung von Arzneimittel für die Behandlung von Nierenfunktionsstörungen

Also Published As

Publication number Publication date
CA2368823A1 (en) 2000-11-16
KR20070040425A (ko) 2007-04-16
IL146232A (en) 2007-06-03
HUP0202399A3 (en) 2003-02-28
WO2000067847A3 (de) 2001-08-02
CN101524356A (zh) 2009-09-09
ATE284693T1 (de) 2005-01-15
PT1176963E (pt) 2005-05-31
AU770671B2 (en) 2004-02-26
JP2011088941A (ja) 2011-05-06
CZ20014015A3 (cs) 2002-02-13
NO20015413L (no) 2001-11-15
EP1176963B1 (de) 2004-12-15
CN1360502A (zh) 2002-07-24
JP2014098044A (ja) 2014-05-29
JP5897054B2 (ja) 2016-03-30
US8785447B2 (en) 2014-07-22
KR100781828B1 (ko) 2007-12-03
CZ301832B6 (cs) 2010-07-07
CN1360502B (zh) 2010-08-04
ZA200110044B (en) 2003-03-06
JP5542713B2 (ja) 2014-07-09
DK1176963T3 (da) 2005-04-25
WO2000067847A2 (de) 2000-11-16
DE19922443A1 (de) 2000-11-09
HUP0202399A2 (hu) 2002-12-28
US20060223793A1 (en) 2006-10-05
NO20015413D0 (no) 2001-11-06
EP1176963A2 (de) 2002-02-06
DE50008964D1 (de) 2005-01-20
ES2234597T3 (es) 2005-07-01
US7098214B1 (en) 2006-08-29
CA2368823C (en) 2008-10-21
HU228516B1 (en) 2013-03-28
JP2002544178A (ja) 2002-12-24
KR20010112474A (ko) 2001-12-20
AU4559100A (en) 2000-11-21
JP4727822B2 (ja) 2011-07-20
BR0010337A (pt) 2002-02-13
NO329325B1 (no) 2010-09-27

Similar Documents

Publication Publication Date Title
IL146232A0 (en) Use of dopamine d3 receptor ligands for producing medicaments for treating kidney disorders
MXPA03010201A (es) Derivados de 2-piridin-ciclohexan-1,4-diamina sustituidos.
IL190654A (en) Methods of Methyl-Sulfonamido-Propanamido, Processes for Preparation and Medicines Containing Them
MXPA03011940A (es) Ligandos del receptor de 5-ht- y sus usos.
SI1888541T1 (sl) Benzo(d)izoksazol-3-il-aminske spojine in njihova uporaba kot ligandi vaniloidnega receptorja
WO1999017755A3 (en) Medicaments
IL210046A0 (en) Ccr1 antagonists for the treatment of i.a. demyelinating inflammatory disease
YU7804A (sh) Stabilni polimorf flibanserina,postupak za njegovo dobijanje u industrijskim razmerama i njegova primena za pripremanje lekova
MX2010006204A (es) Derivados de oxindol 5,6-disubstituidos y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
PT1149078E (pt) Ligandos receptores de 5-ht6 selectivos
ZA200201788B (en) Substituted 1,5-dihydropyrrol-2-on derivatives as NMDA receptor antagonists for the treatment of pain.
MXPA06000701A (es) Compuestos de sulfonildihidrobencimidazolona como ligandos de 5-hidroxitriptamina-6.
ZA987140B (en) Treatment of attention deficit disorders
WO2003039539A3 (de) Verwendung von endothelin-rezeptor-antagonisten zur behandlung von tumorerkrankungen
WO2001049654A3 (de) Substituierte aminomethyl-phenyl-cyclohexanderivate
MXPA04000446A (es) 4-aminociclohexanoles sustituidos.
MXPA04004090A (es) Compuestos substituidos de 1h-quinolin-2-ona.
AU2002358469A8 (en) Modified receptors for the discovery of therapeutic ligands
CY2456B1 (en) At1 receptor antagonist for the stimulation of apoptosis.
MXPA03001472A (es) Compuestos para el tratamiento de trastornos adictivos.
MY127328A (en) 5-amino-1-pentene-3-ol substituted derivatives
AU2001278549A1 (en) Use of pyridazino(4,5-)indole-1-acetamide derivatives for preparing medicines for treating pathologies related to the dysfunction of peripheral benzodiazepin receptors
MXPA04000953A (es) Derivados sustituidos del acido 5,6,6a,11b-tetrahidro-7-oxa-aza-benzo[c]fluoren-6-carboxilico como antagonista de nmda.
UA87292C2 (ru) Применение сирамезина для лечения злокачественных опухолей
TW200407314A (en) Preparation of 4, 6-dichloro-5-fluoropyrimidine

Legal Events

Date Code Title Description
HP Change in proprietorship
FF Patent granted
KB Patent renewed